Evidence map›Paper›PMID 42695019›Full record

ArticleInternational journal of biological sciences2026

AMOTL2 inhibits lymph node metastasis in gastric cancer by suppressing TGF-β/Smad signaling and is destabilized by the E3 ubiquitin ligase SMURF1.

Huizhen Wang, Bo Yang, Changqing Lin, Yigao Wang, Yida Lu, Jing Li, Jianhui Li, Kexun Yu, Mingliang Wang, Pengpeng Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Huizhen WangDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Bo YangDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Changqing LinDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yigao WangDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yida LuDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jing LiDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jianhui LiDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Kexun YuDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Mingliang WangDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Pengpeng LiuDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yuexiang WangShanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China.
Yongxiang LiDepartment of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiomotin-like protein 2 (AMOTL2) regulates cell polarity and cytoskeletal regulation, but its role in gastric cancer (GC) remains undefined. Here, we show that AMOTL2 is frequently downregulated in GC tissues and cell lines, and its low expression is associated with deeper tumor invasion, lymph node metastasis, and shorter overall survival. Gain- and loss-of-function assays demonstrated that AMOTL2 suppresses GC cell proliferation, migration, and invasion. AMOTL2 overexpression also impaired endothelial and lymphatic-endothelial tube formation and reduced the expression of angiogenic and lymphangiogenic factors. In the subcutaneous, orthotopic, and popliteal lymph node metastasis models, AMOTL2 inhibited tumor growth and lymphatic dissemination. Mechanistically, AMOTL2 suppressed TGF-β/Smad signaling, as evidenced by reduced BMP2 and TGF-β1 expression, decreased Smad1/5/9 and Smad2/3 phosphorylation, and impaired Smads nuclear accumulation. Notably, pharmacological Smad1/5/9 activation by SB4 partially reversed the suppressive phenotypes of AMOTL2

Indexed as

Lymphatic MetastasisSmad ProteinsStomach NeoplasmsTransforming Growth Factor betaUbiquitin-Protein LigasesAngiomotinsAnimalsCell Line, TumorCell MovementCell ProliferationHumansMiceMice, NudeSignal TransductionAMOTL2 protein, humanAngiomotinsSmad ProteinsSMURF1 protein, humanTransforming Growth Factor betaUbiquitin-Protein LigasesAMOTL2Gastric cancerSMURF1TGF-β/Smad pathway

Identifiers

PMID42695019
PMCPMC13540700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.